OpenURL Connection Search

Select item for more details and to access through your institution.

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Published in:
Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1220558
By:
- Patra-Kneuer, Maria;
- Gaomei Chang;
- Wendan Xu;
- Augsberger, Christian;
- Grau, Michael;
- Zapukhlyak, Myroslav;
- Ilieva, Kristina;
- Landgraf, Karin;
- Mangelberger-Eberl, Doris;
- Yousefi, Kasra;
- Berning, Philipp;
- Kurz, Katrin S.;
- Ott, German;
- Klener, Pavel;
- Khandanpour, Cyrus;
- Horna, Pedro;
- Schanzer, Jürgen;
- Steidl, Stefan;
- Endell, Jan;
- Heitmüller, Christina
Publication type:
Article
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial.
Published in:
Clinical & Translational Immunology, 2020, v. 9, n. 3, p. 1, doi. 10.1002/cti2.1117
By:
- Lichtenegger, Felix S;
- Schnorfeil, Frauke M;
- Rothe, Maurine;
- Deiser, Katrin;
- Altmann, Torben;
- Bücklein, Veit L;
- Köhnke, Thomas;
- Augsberger, Christian;
- Konstandin, Nikola P;
- Spiekermann, Karsten;
- Moosmann, Andreas;
- Boehm, Stephan;
- Boxberg, Melanie;
- Heemskerk, Mirjam HM;
- Goerlich, Dennis;
- Wittmann, Georg;
- Wagner, Beate;
- Hiddemann, Wolfgang;
- Schendel, Dolores J;
- Kvalheim, Gunnar
Publication type:
Article
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Published in:
Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01163-6
By:
- Tahk, Siret;
- Vick, Binje;
- Hiller, Björn;
- Schmitt, Saskia;
- Marcinek, Anetta;
- Perini, Enrico D.;
- Leutbecher, Alexandra;
- Augsberger, Christian;
- Reischer, Anna;
- Tast, Benjamin;
- Humpe, Andreas;
- Jeremias, Irmela;
- Subklewe, Marion;
- Fenn, Nadja C.;
- Hopfner, Karl-Peter
Publication type:
Article

Found: 3

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial.

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.